# Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

> **NCT00928018** · PHASE3 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 139 (actual)

## Conditions studied

- Non-hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus
- **DRUG:** Cyclosporine
- **DRUG:** MMF

## Key facts

- **NCT ID:** NCT00928018
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2019-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928018, "Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00928018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*